Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
D Planchard, S Popat, K Kerr, S Novello… - Annals of …, 2019 - annalsofoncology.org
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
[PDF][PDF] Corrigendum: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2018) 29 …
D Planchard, S Popat, K Kerr, S Novello… - ANNALS OF …, 2018 - iris.unito.it
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
Corrigendum: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2018) 29 (iv192 …
D Planchard, S Popat, K Kerr… - Annals of …, 2019 - research.manchester.ac.uk
The following corrections are made: In the section" Management of advanced/metastatic
NSCLC, First-line treatment of EGFR-and ALK-negative NSCLC disease, regardless of PD …
NSCLC, First-line treatment of EGFR-and ALK-negative NSCLC disease, regardless of PD …
[引用][C] Correction to:“Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
D Planchard, S Popat, K Kerr, S Novello, EF Smit… - Annals of …, 2019 - cir.nii.ac.jp
Correction to: “Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up” | CiNii Research CiNii 国立情報学研究所 学術情報 …
diagnosis, treatment and follow-up” | CiNii Research CiNii 国立情報学研究所 学術情報 …
[引用][C] Correction to:" Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".
D Planchard, S Popat, K Kerr, S Novello… - Annals of Oncology …, 2019 - europepmc.org
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up". - Abstract - Europe PMC Sign in | Create an account …
diagnosis, treatment and follow-up". - Abstract - Europe PMC Sign in | Create an account …
[PDF][PDF] Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D Planchard, S Popat, K Kerr, S Novello… - Annals of …, 2019 - researchgate.net
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
[PDF][PDF] Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D Planchard, S Popat, K Kerr, S Novello, EF Smit… - 2019 - esmo.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
[引用][C] Correction to:" Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"
D Planchard, S Popat, K Kerr… - Annals of oncology …, 2019 - pubmed.ncbi.nlm.nih.gov
[PDF][PDF] Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D Planchard, S Popat, K Kerr, S Novello, EF Smit… - Annals of …, 2019 - iris.unito.it
1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …
[PDF][PDF] Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D Planchard, S Popat, K Kerr, S Novello, EF Smit… - 2019 - esmo.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …